Taysha Gene Therapies, Inc. Other Current Liabilities
Taysha Gene Therapies, Inc. (TSHA) had Other Current Liabilities of $1.49 million as of 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2022-03-31
- 2021-12-31: Other Liabilities, Current $1.49M.
- 2020-12-31: Other Liabilities, Current $91.00K; Other Liabilities, Current as first filed $264.00K.
- 2019-12-31: Other Liabilities, Current $21.00K.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2021-12-31 | $1.49M 10-K · filed 2022-03-31 | |
| 2020-12-31 | $91.00K 10-K · filed 2022-03-31 | $264.00K 10-K · filed 2021-03-03 |
| 2019-12-31 | $21.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |